Replies to post #71323 on Biotech Values

[genisi]

FOLD

I haven't listened but I see on SI that you already have :)

In the completed four phase II trials, they looked at decrease from baseline in urine GL-3 and also in various organs and tissues where it accumulates. I assume that if reduction in urine GL-3 and tissue GL-3 correlated well, then the FDA might allow them test in urine only.